Has AstraZeneca Fallen Off the Patent Cliff?

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

The patent cliff — the expiration of patents on blockbuster pharmaceuticals — cost drug manufacturers $36 billion in 2012 and will decrease sales by an estimated $25 billion this year.

Fourth quarter results from AstraZeneca (NYSE:AZN) and Eli Lilly (NYSE:LLY) showed the extent that generic competition has deeply hurt their profitability.

London-based AstraZeneca reported quarterly earnings on Thursday of $1.56 per share. While the results beat the expectations of analysts polled by Thomson Reuters by 21 cents, the company’s core earnings fell 3 percent from the year-ago quarter. The pharmaceutical company only avoided a much larger drop by lowering costs and securing a favorable tax adjustment. Its drop in sales was much worse than the decrease in earnings; they declined 16 percent to $7.28 billion, but beat analysts’ estimates of $7.20 billion…

Investors are making great returns as markets roar higher. Join the party. Click here to discover our Feature Stock Pick now!

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business